Cartesian Therapeutics

Cartesian engineers CAR-T using messenger RNA rather than DNA. DNA-based CAR-T permanently integrates into the T-cell genome, requiring lymphodepletion chemotherapy before infusion and carrying risks of cytokine release syndrome and long-term toxicity. Cartesian's mRNA approach produces CAR expression that is transient, eliminating the need for preconditioning chemotherapy and allowing repeat dosing. This makes the therapy suitable for chronic autoimmune conditions where a permanent genetic modification would pose unacceptable risk.

The lead candidate, Descartes-08, is a Phase 2-ready anti-BCMA mRNA CAR-T for myasthenia gravis, a chronic autoimmune disease causing muscle weakness that can become life-threatening. The company has also signaled interest in systemic lupus erythematosus and other B-cell-mediated autoimmune conditions. Descartes-08 targets plasma cells and plasma cell precursors, aiming to reset the autoimmune process rather than simply suppress symptoms.

Carsten Brunn serves as President and CEO. He previously held leadership roles at Bayer, where he managed global pharmaceutical operations, and at Novartis in strategy and business development. His career spans large-pharma commercialization and biotech R&D management. The board includes veterans of cell therapy development and autoimmune clinical research.

No. Cartesian is a clinical-stage company; its programs are in Phase 2 development. There is no approved product generating revenue. The company operates as a pre-commercial biotech funded through public equity markets, listed on Nasdaq under the ticker RNAC, and through grants and partnership agreements.

Conventional CAR-T requires lymphodepletion chemotherapy to clear space in the bone marrow for the engineered cells to engraft. Cartesian's mRNA-engineered cells are infused without this step because they function peripherally and do not need to achieve permanent engraftment. The CAR expression lasts for a defined window, after which the cells return to their normal state, enabling the therapy to be given in an outpatient setting and repeated as needed.

Cartesian Therapeutics is a publicly traded clinical-stage biotechnology company listed on Nasdaq — not a family office or investment firm. It employs scientists and clinicians who design and test mRNA cell therapies, rather than allocating capital to external funds or direct investments. It appears in some alternative-investment databases because public biotech companies can be targets for PIPEs and registered direct offerings, but it is an operating business, not an allocator.

Transient CAR expression means the therapeutic effect degrades over time — Cartesian's model depends on repeat dosing to maintain disease control. The durability of clinical response between doses, the immunogenicity risk of repeated mRNA infusions, and the manufacturing consistency for autologous therapies all represent execution risks not fully resolved at this stage. The Phase 2 data for Descartes-08 has shown encouraging durability in myasthenia gravis, but the commercial profile will depend on the dosing interval and long-term safety record established in registrational trials.